1. "2018"
Formats
  1. Journal Article (3011)
  2. Meeting Abstract (1948)
  3. Book Section (206)
  4. Conference Paper (38)
  5. Book Whole (11)
  6. Editorial (4)
  7. Review (4)
  8. Miscellaneous (2)
  9. Correspondence (1)
Groups
  1. Department of Medicine (2296)
  2. Solid Tumor Oncology Division (1378)
  3. GSK Faculty (1136)
  4. Sloan Kettering Institute Postdocs (1044)
  5. Surgery (870)
  6. Center for Hematologic Malignancies (863)

More Groups

People
  1. Sergio Giralt (87)
  2. Matthew Hellmann (78)
  3. Jedd Wolchok (74)
  4. Marc Ladanyi (74)
  5. Robert Motzer (71)
  6. Nancy Lee (64)

More People

Years
  1. 2018 (5225)
Publications
  1. Journal of Clinical Oncology (562)
  2. Blood (249)
  3. Cancer Research (183)
  4. Annals of Oncology (140)
  5. International Journal of Radiation Oncology, Biology, Physics (137)
  6. Modern Pathology (127)

More Publications

Publishers
  1. Elsevier Inc. (691)
  2. American Society of Clinical Oncology (605)
  3. Springer (410)
  4. American Association for Cancer Research (299)
  5. Oxford University Press (291)
  6. American Society of Hematology (273)

More Publishers

Results (5225)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Assessing the value of nivolumab (NIVO) versus placebo (PBO) and ipilimumab (IPI) as adjuvant therapy for resected melanoma
    Meeting Abstract

    Freeman, M. L.; Shoushtari, A. N.; Betts, K. A.; Gupte-Singh, K.; Du, E. X.; Ritchings, C.; Rao, S.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Immune profiling of BRCA-mutated breast cancers
    Meeting Abstract

    Force, J. M.; Abbott, S.; Broadwater, G.; Stashko, I.; Westbrook, K. E.; Kimmick, G. G.; LeNoir Sammons, S.; Hyslop, T.; Brauer, H. A.; Mashadi-Hossein, A.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Pembrolizumab (pembro) versus investigator's choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC): 2-year follow-up from the phase 3 KEYNOTE-045 trial
    Meeting Abstract

    Fradet, Y.; Bellmunt, J.; De Wit, R.; Vaughn, D. J.; Lee, J. L.; Fong, L.; Vogelzang, N. J.; Climent, M. A.; Petrylak, D. P.; Choueiri, T. K.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • The clinical utility of prospective molecular characterization in advanced cervical and vulvovaginal cancer
    Meeting Abstract

    Friedman, C. F.; Donoghue, M.; Vivek, M.; Aghajanian, C.; Abu-Rustum, N.; Cadoo, K. A.; Grisham, R. N.; Hensley, M. L.; Konner, J. A.; Kyi, C.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • ECOG score analysis as a proxy for health-related quality of life assessment in patients with poor or intermediate risk metastatic renal cell carcinoma from the CABOSUN trial (Alliance A031203)
    Meeting Abstract

    Feldman, D. R.; Feuilly, M.; Meng, J.; Lister, J.; Marteau, F.; Morris, M. J.; George, D. J.; Choueiri, T. K.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Tepotinib in patients with advanced non-small cell lung cancer (NSCLC) harboring MET exon 14-skipping mutations: Phase II trial
    Meeting Abstract

    Felip, E.; Horn, L.; Patel, J. D.; Sakai, H.; Scheele, J.; Bruns, R.; Paik, P. K.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Alterations in serum bilirubin during enasidenib treatment in patients with or without UGT1A1 mutations
    Meeting Abstract

    Fathi, A. T.; Dinardo, C. D.; Kline, I.; Tu, N.; Attar, E. C.; Stein, E. M.; de Botton, S.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • 4-year overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001
    Meeting Abstract

    Felip, E.; Hellmann, M. D.; Hui, R.; Carcereny, E.; Leighl, N. B.; Ahn, M. J.; Eder, J. P.; Balmanoukian, A. S.; Aggarwal, C.; Horn, L.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Genomic landscape, clinical characteristics and outcomes of early onset (EO) compared with average onset (AO) colorectal cancer (CRC)
    Meeting Abstract

    Dos Santos Fernandes, G.; Chatila, W. K.; Yaeger, R.; Mendelsohn, R. B.; Stadler, Z. K.; Segal, N. H.; Varghese, A. M.; Lagunes, D. R.; Diaz, L. A.; Shia, J.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT)
    Meeting Abstract

    Feldman, D. R.; Hu, J.; Srinivas, S.; Stadler, W. M.; Costello, B. A.; Appleman, L. J.; Milowsky, M. I.; Patil, S.; Bromberg, M.; Nolan, P.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save